Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Duvakitug - Teva Pharmaceuticals

Next Previous
X
Search
Drug Profile

Duvakitug - Teva Pharmaceuticals

Alternative Names: SAR-447189; TEV-48574; TEV’574

Latest Information Update: 05 Mar 2025

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Teva Pharmaceutical Industries
  • Class Anti-inflammatories; Antiasthmatics; Monoclonal antibodies
  • Mechanism of Action Tumour necrosis factor ligand superfamily member 15 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Asthma; Crohn's disease; Ulcerative colitis

Most Recent Events

  • 22 Feb 2025 Adverse events and efficacy data from a phase II RELIEVE UCCD trial in Ulcerative colitis or Crohn's disease released by Sanofi
  • 22 Feb 2025 Teva Pharmaceuticals plans a phase III trial for Ulcerative colitis and Crohn's disease (SC) in the second half of 2025
  • 17 Dec 2024 Efficacy and adverse event data from the phase IIb RELIEVE UCCD LTE trial in Ulcerative colitis released by Teva Pharmaceuticals

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top